Genzyme Sues Over Endo's Bid To Sell Generic Renvela
Genzyme claims Endo submitted an abbreviated new drug application to the U.S. Food and Drug Administration that infringes the claims of Genzyme's U.S. Patent No. 5,667,775, which covers phosphate-binding polymers for oral administration and is used to treat patients with chronic kidney disease on dialysis.
Genzyme has aggressively sought to protect...
To view the full article, register now.